Investigating the Role of Buzhong Yiqi Decoction on Neurogenic Bladder with Network Pharmacology, Molecular Docking, and In Vitro Assays
ASSAY and Drug Development Technologies · 2025
DOI: 10.1089/adt.2024.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASSAY and Drug Development Technologies, 2025. Verfasst von Yixin Bao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Network Pharmacology, Molecular Docking Simulation, Urinary Bladder, Neurogenic. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
Buzhong Yiqi decoction (BZYQD) is a traditional Chinese medicine prescription for treating neurogenic bladder (NB). However, the underlying pharmacological mechanism remains unclear. This study aims to clarify the related molecular mechanism. Molecular structure information and targets of core components of BZYQD were obtained from Traditional Chinese Medicines Systems Pharmacology Platform (TCMSP) and SwissTargetPrediction databases. Genes involved in NB were obtained from Comparative Toxicogenomics Database, DisGeNet, GeneCards, and Online Mendelian Inheritance in Man databases. The hub targets of BZYQD in NB treatment were identified by protein-protein interaction (PPI) network analysis with STRING platform and analyzed by gene ontology analysis and the Kyoto Encyclopedia of Genes and Genomics pathway enrichment analysis. Molecular docking was used to verify the binding affinity between the hub targets and the bioactive components of BZYQD. Subsequently, the neuroprotective and anti-inflammatory effects of main bioactive components of BZYQD were investigated with in vitro assays. A total of 131 candidate compounds and 925 predicted target genes were screened. PPI network analysis suggested that ESR1, EGFR, HSP90AA1, MAPK3, AKT1, and CASP3 were the hub targets. BZYQD treatment was associated with hypoxia inducible factor-1 (HIF-1) signaling pathway. Dehydroglyasperin C (DGC), N-cis-feruloyltyramine, shinpterocarpin (SHI), gancaonin M, and glyasperin B, as the main bioactive components of BZYQD, had good binding affinity with hub target proteins. DGC and SHI treatment could significantly inhibit the injury of neurons and inflammatory response of microglia stimulated by oxidized low-density lipoprotein (ox-LDL), respectively. In summary, BZYQD and its main bioactive components DGC and SHI show good potential to ameliorate the symptoms of NB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Department of Urology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
ORCID-Profile: Chun Sun
Zitieren
APA
Bao, Y., & Sun, C. (2025). Investigating the Role of Buzhong Yiqi Decoction on Neurogenic Bladder with Network Pharmacology, Molecular Docking, and In Vitro Assays. ASSAY and Drug Development Technologies. https://doi.org/10.1089/adt.2024.028
Vancouver
Bao Y, Sun C. Investigating the Role of Buzhong Yiqi Decoction on Neurogenic Bladder with Network Pharmacology, Molecular Docking, and In Vitro Assays. ASSAY and Drug Development Technologies. 2025. doi:10.1089/adt.2024.028
BibTeX
@article{Bao2025,
author = {Bao, Yixin and Sun, Chun},
title = {Investigating the Role of Buzhong Yiqi Decoction on Neurogenic Bladder with Network Pharmacology, Molecular Docking, and In Vitro Assays},
journal = {ASSAY and Drug Development Technologies},
year = {2025},
doi = {10.1089/adt.2024.028}
}
EUVIMED